ClinicalTrials.gg
CompletedNCT04647708Updated Feb 21, 2024

Study of M5049 in CLE and SLE Participants

A Phase 1 interventional study of M5049 and M5049 in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 12 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-21.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany — 3 open to participants now, 4 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Merck KGaA, Darmstadt, Germany.

Enrollment
10th of 12
25 · median 280
Started
2020
the only one that year
Phase 1
2 of 12
none open now
Registered
7th of 12
by date

Among the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1, and was the 7th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

3 of the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, or all of them as a file.
02

Study summary

This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE).

03

Conditions studied

  • Systemic Lupus Erythematosus
  • Cutaneous Lupus Erythematosus

Keywords

  • Lupus Erythematosus, Systemic
  • Lupus Erythematosus, Cutaneous
  • Autoimmune Diseases
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active systemic lupus erythematosus (SLE) with a Cutaneous lupus erythematosus disease area and activity index (CLASI-A) greater than or equal to [>= ] 6 and/or at least one active SLE clinical manifestation according to Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
  • Active cutaneous lupus erythematosus (CLE) (subacute cutaneous lupus erythematosus and/or discoid lupus erythematosus) with a CLASI-A >= 6
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • or rheumatic disease other than SLE or CLE
  • Dermatological diseases other than cutaneous manifestations of SLE or CLE
  • Uncontrolled medical conditions including significant cardiovascular events, active lupus nephritis, and active neurological disorder
  • Ongoing or active viral, bacterial or fungal infection
  • History of uncontrolled seizures or other neurological disorder
  • History of or positive for , virus, or virus
  • History of
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Part A (Cohort 1): M5049 Dose A

    Drug: M5049

  • Experimental
    Part A (Cohort 2): M5049 Dose B

    Drug: M5049

  • Experimental
    Part A (Cohort 3): M5049 Dose C

    Drug: M5049

  • Experimental
    Part A (Cohort 4): M5049 Dose D

    Drug: M5049

  • Placebo comparator
    Part A: Placebo

    Drug: Placebo

  • Experimental
    Part B (Cohort 5): M5049 Dose E

    Drug: M5049

  • Placebo comparator
    Part B: Placebo

    Drug: Placebo

Interventions

  • DrugM5049

    Participants will receive low oral dose of M5049, twice daily in Part A.

  • DrugM5049

    Participants will receive ascending oral dose of M5049, twice daily in Part A.

  • DrugM5049

    Participants will receive high oral dose of M5049, twice daily in Part B.

  • DrugPlacebo

    Participants will receive placebo matched to M5049.

06

What researchers measure

Primary outcomes

  1. Part A: Cohort 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Event of Special Interest (AESI), TEAEs Leading to Permanent Treatment Discontinuation and Treatment-Related TEAEs

    Time frame: Up to Day 102

  2. Part A: Cohort 3 and 4; Part B: Cohort 5: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Event of Special Interest (AESI), TEAEs Leading to Permanent Treatment Discontinuation and Treatment-Related TEAEs

    Time frame: Up to Day 186

  3. Part A: Cohort 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Based on Severity

    Time frame: Up to Day 102

  4. Part A: Cohort 3 and 4; Part B: Cohort 5: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Based on Severity

    Time frame: Up to Day 186

  5. Part A: Cohort 1 and 2: Number of Participants with Clinically Significant Changes from Baseline in Laboratory Parameters, Vital Signs, Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings

    Time frame: Up to Day 102

  6. Part A: Cohort 3 and 4; Part B: Cohort 5: Number of Participants with Clinically Significant Changes from Baseline in Laboratory Parameters, Vital Signs, Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings

    Time frame: Up to Day 186

  7. Part A: Cohort 1 and 2: Number of Participants with Confirmed Signs and Symptoms of Prodromal Seizure

    Time frame: Up to Day 102

  8. Part A: Cohort 3 and 4; Part B: Cohort 5: Number of Participants with Confirmed Signs and Symptoms of Prodromal Seizure

    Time frame: Up to Day 186

  9. Part A: Cohort 1 and 2: Number of Participants with Suicidal Behavior and Suicidal Ideation as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Day 102

Secondary outcomes

  1. Part A and Part B: Maximum Observed Plasma Concentration (Cmax) of M5049

    Time frame: Pre-dose up to Day 85 for Cohort 1 and 2 of Part A, up to Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B

  2. Part A and Part B: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M5049

    Time frame: Day 1 and Day 29

  3. Part A and Part B: Time to Reach Maximum Plasma Concentration (tmax) of M5049

    Time frame: Pre-dose up to Day 85 for Cohort 1 and 2 of Part A, up to Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B

  4. Part A and Part B: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) of M5049

    Time frame: Pre-dose up to Day 85 for Cohort 1 and 2 of Part A, up to Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B

  5. Part A and Part B: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t/Dose) of M5049

    Time frame: Day 1 and Day 29

  6. Part A and Part B: Accumulation Ratio for Maximum Observed Plasma Concentration (Racc Cmax) of M5049

    Time frame: Pre-dose up to Day 85 for Cohort 1 and 2 of Part A, up to Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B

  7. Part A and Part B: Elimination Rate Constant (Lambda z) of M5049

    Time frame: Day 1 and Day 29

  8. Part A and Part B: Apparent Terminal Half-life (t1/2) of M5049

    Time frame: Day 1 and Day 29

  9. Part A and Part B: Area Under the Plasma Concentration-Time Curve From Time Zero to 12 Hours Post-Dose (AUC0-12h) of M5049

    Time frame: Day 29

  10. Part A and Part B: Dose Normalized Area Under Plasma Concentration-Time Curve from Time Zero to 12 Hours Post-Dose (AUC0-12h/Dose) of M5049

    Time frame: Day 29

  11. Part A and Part B: Total Body Clearance (CL/f) of M5049

    Time frame: Day 1

  12. Part A and Part B: Apparent Volume of Distribution (Vz/f) of M5049

    Time frame: Day 1

  13. Part A and Part B: Area Under Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of M5049

    Time frame: Day 1

  14. Part A and Part B: Dose Normalized Area Under Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-inf/Dose) of M5049

    Time frame: Day 1

  15. Part A and Part B: Change from Baseline in Cutaneous Lupus Erythematosus Disease Area and Activity Index (CLASI-A)

    Time frame: Baseline (Day 1) through Day 85 for Cohort 1 and 2 of Part A, Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B

  16. Part A and Part B: Change from Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

    Time frame: Baseline (Day 1) through Day 85 for Cohort 1 and 2 of Part A, Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B

  17. Part A and Part B: Change from Baseline in 28-Joint Count

    Time frame: Baseline (Day 1) through Day 85 for Cohort 1 and 2 of Part A, Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B

  18. Part A and Part B: Change from Baseline in Physician Global Assessment (PGA) Score

    Time frame: Baseline (Day 1) through Day 85 for Cohort 1 and 2 of Part A, Day 169 for Cohort 3, 4 of Part A and Cohort 5 of Part B

07

Study locations

12 sites
  • Medical center Medconsult Pleven OOD
    Pleven, Bulgaria
  • Medical Center-1-Sevlievo EOOD
    Sevlievo, Bulgaria
  • Military Medical Academy - MHAT - Sofia
    Sofia, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, Bulgaria
  • SocraTec R&D GmbH
    Erfurt, Germany
  • Fraunhofer ITMP (Fraunhofer Institute for Translational Medicine and Pharmacology)
    Frankfurt, Germany
  • ARENSIA Exploratory Medicine Phase I Unit, Clinical Republican Hospital
    Chisinau, Moldova, Republic of
  • PHI University Clinic of Rheumatology Skopje
    Skopje, North Macedonia
  • Hospital Universitario Nuestra Señora de Valme
    Sevilla, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, Spain
  • Hospital Universitario Rio Hortega - Servicio de Medicina Interna
    Valladolid, Spain
  • Medical Center of Limited Liability Company "Harmoniya krasy", Department of clinical trials
    Kyiv, Ukraine
08

References and documents

Publications

  • Klopp-Schulze L, Shaw JV, Dong JQ, Khandelwal A, Vazquez-Mateo C, Goteti K. Applying Modeling and Simulations for Rational Dose Selection of Novel Toll-Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical Need. Clin Pharmacol Ther. 2022 Aug;112(2):297-306. doi: 10.1002/cpt.2606. Epub 2022 May 21. PubMed 35390178 ↗

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://bit.ly/IPD21

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Dec 2023, 36 months.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 36 months is above that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2020
First posted
Dec 1, 2020
StartActual
Dec 16, 2020
Primary completionActual
Dec 19, 2023
CompletionActual
Dec 19, 2023
Last update
Feb 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04647708
Responsible party
Sponsor
First posted
Dec 1, 2020
Start date
Dec 16, 2020
Primary completion
Dec 19, 2023
Completion
Dec 19, 2023
Last update
Feb 21, 2024

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enpatoran

Start the discussion